Analysis of G2 checkpoint abrogation to overcome drug resistance in head and neck cancers

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592591
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: University of Fukui
• Principal Investigator: NARITA Norihiko 福井大学, 医学部附属病院, 講師 (80345678)
• Co-Investigator(Kenkyū-buntansha): MATSUMOTO Hideki 福井大学, 高エネルギー医学研究センター, 准教授 (40142377)
• Co-Investigator(Renkei-kenkyūsha): ITO Yumi 福井大学, 医学部附属病院, 医員 (00646458) ; TAKABAYASHI Tetsuji 福井大学, 医学部, 助教 (70397272) ; YAMADA Takechiyo 福井大学, 医学部附属病院, 講師 (70283182) ; FUJIEDA Shigeharu 福井大学, 医学部, 教授 (30238539) ; KARAYA Kazuhiro 福井大学, ライフサイエンス支援センター, 助手 (70233997)
• Research Collaborator: SUGIMOTO Chizuru ; NOMI Nozomi
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: PCBP4 / head and neck cancer / cisplatin / resistance / G2 checkpoint

Outline of Final Research Achievements

The present study showed that suppression of PCBP4 by RNAi reduced cisplatin-induced G2/M arrest and enhanced apoptosis in IMC-3CR cells, resulting in the reduction of cisplatin resistance. In contrast, overexpression of PCBP4 in IMC-3 cells induced G2/M arrest after cisplatin treatment and enhanced cisplatin resistance. We revealed that PCBP4 combined with Cdc25A and suppressed the expression of Cdc25A, resulting in G2/M arrest. PCBP4 plays important roles in the induction of cisplatin resistance in human maxillary cancers. PCBP4 is a novel molecular target for the therapy of head and neck cancers, especially cisplatin-resistant cancers.

Free Research Field

耳鼻咽喉科学